BRAF inhibitor unveils its potential against advanced melanoma
- PMID: 20951940
- DOI: 10.1016/j.ccr.2010.10.001
BRAF inhibitor unveils its potential against advanced melanoma
Abstract
Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.
Copyright © 2010 Elsevier Inc. All rights reserved.
Comment on
-
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. Clin Cancer Res. 2008. PMID: 18676756 Clinical Trial.
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454. Nature. 2010. PMID: 20823850 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
